BCM
CARM

Bridgeway Capital Management’s Carisma Therapeutics CARM Stock Holding History

Bridgeway Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,988
Closed -$8.49K – 1234
2025
Q3 		$8.49K Hold
30,988
– – ﹤0.01% 1195
2025
Q2 		$12.1K Hold
30,988
– – ﹤0.01% 1172
2025
Q1 		$9.61K Hold
30,988
– – ﹤0.01% 1169
2024
Q4 		$13K Buy
30,988
+550
+2% +$453 ﹤0.01% 1189
2024
Q3 		$29.9K Buy
30,438
+1,474
+5% +$1.6K ﹤0.01% 1237
2024
Q2 		$44K Sell
28,964
-185,920
-87% -$277K ﹤0.01% 1230
2024
Q1 		$488K Sell
214,884
-96,150
-31% -$231K 0.01% 939
2023
Q4 		$911K Buy
311,034
+107,224
+53% +$319K 0.02% 781
2023
Q3 		$862K Buy
203,810
+3,476
+2% +$22K 0.02% 747
2023
Q2 		$1.76M Buy
200,334
+181,324
+954% +$987K 0.04% 582
2023
Q1 		$58.9K Buy
+19,010
New +$181K ﹤0.01% 1297
2022
Q4 		– Sell
-12,500
Closed -$106K – 1381
2022
Q3 		$106K Hold
12,500
– – ﹤0.01% 1258
2022
Q2 		$203K Hold
12,500
– – ﹤0.01% 1088
2022
Q1 		$151K Hold
12,500
– – ﹤0.01% 1212
2021
Q4 		$204K Buy
+12,500
New +$252K ﹤0.01% 1162
2021
Q3 		– Sell
-35,575
Closed -$3.29M – 1291
2021
Q2 		$3.29M Sell
35,575
-6,350
-15% -$405K 0.06% 437
2021
Q1 		$2.18M Hold
41,925
– – 0.04% 572
2020
Q4 		$1.13M Hold
41,925
– – 0.02% 722
2020
Q3 		$1.17M Sell
41,925
-4,250
-9% -$85K 0.03% 616
2020
Q2 		$665K Buy
46,175
+25,325
+121% +$342K 0.01% 776
2020
Q1 		$234K Hold
20,850
– – 0.01% 1011
2019
Q4 		$434K Buy
20,850
+10,000
+92% +$230K 0.01% 1039
2019
Q3 		$254K Buy
10,850
+850
+9% +$19.9K ﹤0.01% 1132
2019
Q2 		$300K Hold
10,000
– – ﹤0.01% 1099
2019
Q1 		$206K Buy
10,000
+5,000
+100% +$86.3K ﹤0.01% 1220
2018
Q4 		$142K Hold
5,000
– – ﹤0.01% 1263
2018
Q3 		$215K Buy
+5,000
New +$195K ﹤0.01% 1311
2018
Q1 		– Sell
-3,250
Closed -$53K – 1383
2017
Q4 		$53K Hold
3,250
– – ﹤0.01% 1367
2017
Q3 		$103K Hold
3,250
– – ﹤0.01% 1339
2017
Q2 		$102K Hold
3,250
– – ﹤0.01% 1356
2017
Q1 		$143K Buy
+3,250
New +$135K ﹤0.01% 1313
2016
Q2 		– Sell
-2,500
Closed -$16K – 1438
2016
Q1 		$16K Hold
2,500
– – ﹤0.01% 1420
2015
Q4 		$151K Hold
2,500
– – ﹤0.01% 1340
2015
Q3 		$121K Hold
2,500
– – ﹤0.01% 1375
2015
Q2 		$141K Buy
2,500
+1,564
+167% +$221K ﹤0.01% 1402
2015
Q1 		$167K Sell
936
-827
-47% -$181K ﹤0.01% 1358
2014
Q4 		$419K Buy
1,763
+935
+113% +$210K 0.01% 1126
2014
Q3 		$184K Buy
+828
New +$197K ﹤0.01% 1347

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Bridgeway Capital Management's CARM Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 30,988 shares — an estimated $8.49K sold.

Bridgeway Capital Management first reported a position in CARM in Q3 2014 and held it in 38 quarters. The position peaked at $3.29M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Bridgeway Capital Management reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 30,988 Carisma Therapeutics shares in Q4 2025, an estimated $8.49K.
  • Bridgeway Capital Management first reported a position in Carisma Therapeutics in Q3 2014 and held it in 38 quarters.
  • Bridgeway Capital Management's Carisma Therapeutics position peaked at $3.29M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.